Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now

Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the oversold stocks to buy right now. On May 12, Maze Therapeutics highlighted in their corporate and financial update positive topline data from the Phase 2 HORIZON trial of MZE829. The trial evaluated the oral inhibitor in patients with APOL1-mediated kidney disease/AMKD. The results provided clinical proof-of-concept, showing meaningful reductions in proteinuria across broad patient populations, including those with focal segmental glomerulosclerosis.

Following these findings, the company is preparing to advance MZE829 into a pivotal trial for moderate AMKD patients without diabetes, which is planned for H1 2027. The company is also progressing its clinical pipeline for MZE782, an oral small molecule targeting PKU and chronic kidney disease. Maze expects to initiate Phase 2 proof-of-concept trials for this candidate by mid-2026 for PKU and in the second half of 2026 for CKD, with topline PKU data anticipated in 2027.

Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now

robina-weermeijer–szKjHyPq28-unsplash

These developments are central to the company’s broader strategy of using genetic insights to address high-unmet needs in metabolic and kidney health. Financially, Maze Therapeutics Inc. (NASDAQ:MAZE) maintains a strong position with $528 million in cash and marketable securities, bolstered by an April 2026 registered offering and a $20 million milestone payment. This capital is expected to fund operations into 2029.

Maze Therapeutics Inc. (NASDAQ:MAZE) is a developer of small-molecule precision medicines for the treatment of kidney and metabolic illnesses.

While we acknowledge the risk and potential of MAZE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MAZE and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1